skip to Cookie NoticeSkip to contents

Notice of privacy incident at Brigham and Women's Hospital Click for more information

Header Skipped.

Press Releases

April 21, 2023

Artificial Intelligence algorithm may help better guide oropharynx cancer treatment

For patients with human papilloma virus (HPV)-associated oropharynx cancer, assessing the presence of cancer cells beyond the lymph nodes, or extranodal extension (ENE), is critical in determining proper treatment. However, ENE is often challenging to detect on imaging pre-treatment, which can lead to an escalation in treatment resulting in greater toxicity and worse quality of life outcomes. However, a new study by investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, and Dana-Farber Brigham Cancer Center found that an artificial intelligence (AI)-based algorithm was superior at detecting ENE compared to four expert head and neck radiologists in a large, multicenter oropharynx cancer clinical trial. This technology is now set to be used in a clinical trial to determine if it results in improved treatment outcomes. The team’s results are published in The Lancet Digital Health.

“HPV-associated oropharynx cancer is now the most common type of this cancer. And while these patients tend to respond very well to surgery or chemotherapy and radiation, there's been a lot of interest in trying to figure out ways to de-escalate treatment, so patients can have fewer side effects and long-term issues that reduce quality of life,” said first author Benjamin Kann, MD. “An appealing strategy is to use a type of minimally invasive surgery for these patients, called trans oral robotic surgery (TORS), instead of seven weeks of combined chemotherapy and radiation.”

However, the presence of ENE is a risk factor for the cancer to return after surgery and for lower rates of survival overall, making patients with ENE poor candidates for TORS. “If ENE is found after surgery, those patients still need to receive a long course of chemotherapy and radiation, or trimodality therapy, which is associated with the worst complications and quality of life outcomes,” said Kann.

Historically, ENE has been very difficult to detect using traditional diagnostic imaging, so there have been a good number of patients who still require trimodality therapy, despite screening. “The unmet need and the impetus for using AI in this study was to see if we could do a better job at predicting whether ENE was present or not on a CT scan prior to treatment, so we can help select the appropriate patients for surgery or for chemotherapy and radiation,” said Kann.

The team had already developed a deep AI algorithm that was trained to detect ENE and showed a high level of accuracy in several datasets. For this study, the team conducted a retrospective evaluation of the AI algorithm’s performance, using pretreatment CTs and corresponding surgical pathology reports from ECOG-ACRIN Cancer Research Group E3311, a multicenter, phase 2 de-escalation trial.

“What was important about this study is it tested the algorithm in the context of a very large randomized clinical trial, where patients who were enrolled, by definition, were supposed to be screened out for having ENE, and yet a significant portion still ended up having ENE,” said Kann. “When we applied the algorithm to this population to see how it would have done in predicting ENE, we found that it performed well with a high degree of accuracy — better than all four expert head and neck radiologists.

“The main benefit seems to be an increase in sensitivity, or a lower percentage of missed ENE,” said Kann. “Ideally, better recognition of ENE in pre-treatment would result in a lower rate of trimodality therapy and improved quality of life for patients.”

These findings suggest that integrating this AI algorithm into the clinic may give physicians more accurate information about the presence of ENE, and determining which patients may be best served by surgery or with chemotherapy and radiation.

Disclosures: Dr. Kann reports research support from the US National Institutes of Health (NIH; grant number K08DE030216-01) and the Radiological Society of North America, honoraria from Dedham Group, and stock options in Monogram Orthopedics. Dr. Schoenfeld reports research support paid to their institution from Merck, Bristol Myers Squibb (BMS), Regeneron, Debiopharm, and Merck KGA; consulting, scientific advisory board, and travel fees from Castle Biosciences, Genentech, Immunitas, Debiopharm, BMS, Nanobiotix, Tilos, AstraZeneca, LEK Consulting, Catenion, ACI Clinical, Astellas, Stimit, and Merck KGA; expert witness fees; stock options in Immunitas; and equity in Doximity. Dr. Haddad reports payment for consulting from Celgene, Nanobiotix, ISA, Merck, Eisai, BMS, AstraZeneca, Pfizer, Loxo, Genentech, Immunomic Therapeutics, GlaxoSmithKline, Gilead Sciences, Vaccinex, Emmanuel Merck Darmstadt (EMD), Serono, BioNTech, Achilles Therapeutics, Bayer, Coherus Biosciences, Boehringer Ingelheim, and Mirati Therapeutics; and research funding from Boehringer Ingelheim, Merck, BMS, Celgene, AstraZeneca, Genentech, Pfizer, Kura Oncology, EMD, and Serono. Dr. Aneja reports research support from the Agency for Healthcare Research and Quality, National Cancer Institute, National Science Foundation, American Cancer Society, American Society of ClinicalOncology, Amazon, and Patterson Trust; fees from American Society of Clinical Oncology, HighCape Capital, Emmerson Collective; and stock options in Prophet Brand Strategy. HJWLA reports research support from NIH (grant numbers U24CA194354, U01CA190234, U01CA209414, and R35CA22052), and the European Union—European research Council (grant number 866504) and stock and other ownership interests in Onc.Ai, Love Health, Health-AI, and Bayerische Motoren Werke AG. Dr. Burtness reports a consulting or advisory role with Merck, Debiopharm Group, CUE Biopharma, Maverick Therapeutics, Rakuten Medical, Nanobiotix, Macrogenics, ALX Oncology, IO Biotech, Ipsen, Genentech/Roche, Kura Oncology, Merck KGA, Pharmaceutical Product Development Global, and Exelixis; research funding to their institution from Merck, Aduro Biotech, Formation Biologics, BMS, and CUE Biopharma; and travel, accommodations, or expenses from Merck and Debiopharm Group. RLF reports stock and other ownership interests in Novasenta; a consulting or advisory role with Merck, Pfizer, EMD Serono, Numab, Macrogenics, Aduro Biotech, Novasenta, Sanofi, Zymeworks, and BMS; and research funding from Bristol Myers Squibb, AstraZeneca/MedImmune, Merck, Tesaro, and Novasenta. All other authors declare no competing interests.

Funding: ECOG-ACRIN Cancer Research Group and the National Cancer Institute of the U.S. National Institutes of Health

Paper cited: Kann B, et al. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. Lancet Digital Health, 2023. DOI: 10.1016/S2589-7500(23)00046-8